GB-0895
Phase 3Small molecule
GB-0895 is one of 21 small molecule programs targeting Asthma. It is currently in Phase 3.
1
Indications
3
Total Trials
3
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Cinqair
TevaPreclinical
GB-0895
GGenerate Biomedicines
Phase 3
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Spiriva
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ozone
TTanta University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GB-0895. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGenerate Biomedicines